Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects

Inclusion Criteria:

- At least 18 years of age at the time of screening.

- Documented diagnosis of HAE (Type I or II)

- Experiencing ≥2 HAE attacks per year, with at least 1 attack in the past 6 months
reported by the subject.

- Willing and able to read, understand, and sign an informed consent form.

- Females of childbearing potential must agree to be abstinent or else use acceptable
forms of contraception throughout study

- Males with female partners of childbearing potential must agree to be abstinent or
use a medically acceptable form of contraception throughout study.

Exclusion Criteria:

- Exposure to an investigational drug or device within 90 days prior to study.

- History of exposure within the past 5 years to a monoclonal antibody or recombinant
protein bearing an Fc domain.

- Concomitant diagnosis of another form of chronic angioedema

- Use of long-term prophylaxis for HAE within 90 days prior to study.

- Use of C1-INH that exceeds a total of 30 days within the past 90 days prior to study;
any use of C1-INH within 7 days prior to study.

- Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing
medications with systemic absorption within 90 days prior to study.

- Exposure to androgens within 90 days prior to study.

- Presence of an indwelling catheter.

- Diagnosis of HIV.

- Active liver disease or liver function test abnormalities

- History of substance abuse or dependence.

- Pregnancy or breastfeeding.

- Any condition that, in the opinion of the Investigator, may compromise their safety
or compliance, preclude successful conduct of the study, or interfere with
interpretation of the results